Clear Cell Chondrosarcoma

Clear cell chondrosarcoma is a rare, low-grade malignant cartilage-forming tumour defined by sheets of tumour cells with abundant clear, glycogen-rich cytoplasm, admixed osteoclast-type giant cells and intralesional woven bone formation. It was delineated as a distinct entity by Unni and colleagues at the Mayo Clinic in 1976 and remains recognised as a separate variant in the WHO classification of bone tumours.

Key epidemiological features

• Accounts for roughly 1 to 2 percent of chondrosarcomas — most units see a handful of cases in a career.
• Peak incidence in the third to fifth decades; a male-to-female ratio of about 2 to 3 : 1.
• Site distribution: proximal femur (femoral head/neck) is the commonest by a wide margin, then proximal humerus; proximal tibia, distal femur, spine, ribs and craniofacial bones are described but uncommon.
• Almost always epiphyseal or epiphyseal-equivalent (apophyses, small round bones); extension into the metaphysis occurs with growth.

Biological behaviour. It is conventionally regarded as grade 1 in behaviour: slow growing, locally destructive, low metastatic propensity. But it is not benign — untreated or inadequately treated disease recurs locally, and metastases to lung and to other bones are well documented, sometimes after very long latency. Recurrent tumours may show dedifferentiation to high-grade sarcoma, which carries a poor prognosis.

Macroscopic. Soft to gritty, grey-white to reddish-brown tissue; cystic haemorrhagic areas are common; gritty foci correspond to woven bone and mineralised cartilage. The lesion abuts and may breach the subchondral plate.

Microscopic — the diagnostic triad

1. Clear cells: sheets and lobules of large, round to polygonal cells with abundant, empty-appearing (glycogen-rich) cytoplasm, sharply defined cell membranes, and central rounded nuclei with fine chromatin and small nucleoli. Mitoses are scarce.
2. Osteoclast-type multinucleated giant cells: scattered throughout — this is why it is misread as chondroblastoma or giant cell tumour.
3. Intralesional woven bone: irregular trabeculae of reactive and tumour-derived woven bone within the lesion. A malignant cartilage tumour that forms bone — this is the feature that clinches it and also the feature that leads to the erroneous diagnosis of osteosarcoma if the cartilage component is under-sampled.

Additional features: low-grade hyaline cartilage lobules (present in most cases, sometimes focal), secondary aneurysmal bone cyst change, and areas indistinguishable from conventional grade 1 chondrosarcoma.

Special stains and immunohistochemistry

• PAS positive, diastase sensitive cytoplasm (glycogen).
• S100 positive — confirms chondroid lineage.
• Cytokeratin, EMA, PAX8, CD10 negative — excludes metastatic clear cell renal carcinoma.
• H3K36M immunostain negative — chondroblastoma is positive (H3F3B K36M mutation); this is a genuinely useful modern discriminator.
• IDH1/IDH2 mutations, characteristic of conventional chondrosarcoma and enchondroma, are generally not a feature of clear cell chondrosarcoma.

• Stage using the Enneking (MSTS) system for surgical staging: this is a low-grade (G1) lesion, usually intracompartmental (T1) unless there is soft tissue extension or joint contamination, and M0 — hence Stage IA or IB. Stage III denotes metastatic disease.
• The AJCC staging for bone sarcoma may also be quoted (grade, size, and presence of skip or distant metastasis).
• Full staging package: whole-bone MRI with contrast, CT of the lesion, CT chest, bone scan or whole-body MRI, baseline bloods.
• Discuss every case at a specialist bone and soft tissue sarcoma MDT with a bone tumour pathologist, musculoskeletal radiologist, sarcoma oncologist and orthopaedic oncology surgeon before any definitive procedure.
• Consent discussion should include limb salvage versus amputation, implant survivorship, function expectations and the requirement for lifelong follow-up.

Other differentials for an adult epiphyseal lytic lesion

Technique

• Preferred: image-guided (CT or ultrasound) core needle biopsy, multiple cores from the solid enhancing component, avoiding cystic or necrotic areas identified on post-contrast MRI.
• Tract: longitudinal, in line with the planned incision, through a single compartment. For the proximal femur, an anterolateral tract in line with a lateral or anterolateral approach; mark the entry point with ink or a suture and record it in the operation note and imaging report so it can be excised en bloc.
• Avoid: transgluteal tracts, crossing the hip joint capsule unnecessarily, traversing neurovascular bundles, and traversing the deltoid in multiple planes at the shoulder.
• Open incisional biopsy if core sampling is non-diagnostic; meticulous haemostasis, no drains through separate stab incisions (or place the drain exit in line with the incision so it can be excised).
• Send tissue for histology, microbiology and fresh tissue for molecular studies where available.

Common pitfalls

• Sampling only the secondary aneurysmal bone cyst component and reporting "aneurysmal bone cyst" — always correlate with the enhancing solid nodule on MRI.
• A frozen section report of "chondroblastoma-like lesion with giant cells" leading directly to curettage on the same list. Never proceed to definitive treatment on frozen section for an adult epiphyseal cartilage lesion.
• Failure to obtain a second opinion from a specialist bone tumour pathologist — this variant is rare and the misdiagnosis rate outside referral centres is meaningful.

Decision map

Adjuvants

• Chemotherapy: ineffective. Cartilage matrix, low mitotic rate and poor drug penetration; there is no evidence of survival benefit in low-grade cartilage malignancy. Reserve consideration for dedifferentiated recurrence, where a high-grade sarcoma protocol may be discussed.
• Radiotherapy: ineffective as primary treatment. Reserved for unresectable disease, close/positive margins where re-resection is impossible, or palliation. Proton or carbon-ion therapy is used in some centres for axial unresectable chondrosarcoma.
• Surgery is the only reliably curative modality. Say this plainly in the viva.

Prognostic determinants

• Surgical margin is the dominant modifiable factor. Wide resection yields long-term disease-free survival in the great majority; intralesional treatment produces high recurrence.
• Metastasis at presentation, large tumour size, axial location and dedifferentiation in recurrent disease predict worse survival.
• Overall survival after adequate wide resection is commonly reported in excess of 85 percent at 5 to 10 years in collected series, but the survival curve does not plateau — late events occur.

Surveillance schedule (representative; adapt to unit protocol)

Global epidemiology and access. Clear cell chondrosarcoma is rare and geographically uniform in distribution; there is no established ethnic or regional predilection. What varies enormously is time to diagnosis and access to a sarcoma centre. In high-income systems with established referral pathways, most patients reach a bone tumour unit before any surgical intervention. In settings with limited MRI access and no centralised sarcoma service, the most common pathway is inadvertent curettage of a presumed benign cyst, followed by late referral with contaminated tissue planes.

Society guidance that genuinely addresses this tumour

Registry and reconstruction evidence. Because tumour endoprostheses are implanted in small numbers, the informative datasets are national and international bone tumour registries and implant registries (for example the Australian Orthopaedic Association National Joint Replacement Registry and the National Joint Registry, both of which capture tumour prostheses, alongside dedicated sarcoma registries such as those of the Rizzoli Institute and the Netherlands Committee on Bone Tumours). Consistent messages: infection and aseptic loosening dominate late failure; revision burden accumulates in young patients over decades; and cumulative implant survivorship falls steadily beyond ten years, which is precisely the horizon relevant to a 30-year-old with a curable low-grade tumour. Consent must reflect a lifetime of revision surgery, not just the index operation.

Practice variation by resource setting

• Where modular tumour endoprostheses are unavailable, osteoarticular allograft, allograft-prosthetic composite, resection-arthrodesis or resection without reconstruction are legitimate reconstructions; the oncological principle (wide margin) is not negotiable, the reconstruction is.
• Where MRI is limited, whole-bone plain radiography plus CT with careful clinical correlation should still identify the epiphyseal lesion; the imperative is referral before intervention.
• Telepathology and international second-opinion networks materially reduce misdiagnosis of this rare variant and should be used where local specialist bone pathology is unavailable.

1. Is intralesional treatment ever acceptable? A minority argue that a very small, entirely intraosseous, radiologically contained lesion could be treated by meticulous extended curettage with adjuvants, preserving a native hip in a young adult. The counter-argument is that recurrence rates after intralesional treatment are unequivocally higher in every published series, recurrences may dedifferentiate, and the tumour is curable with wide resection. Current consensus: wide resection is standard; intralesional treatment should be an exceptional, MDT-documented decision.

2. Endoprosthesis versus osteoarticular allograft in the proximal femur and humerus. Endoprostheses give immediate stability and reliable early function but accrue infection, loosening and revision over decades. Allografts offer soft tissue reattachment and bone stock but carry fracture, non-union, resorption and joint degeneration. Allograft-prosthetic composites attempt to combine both. No randomised data exist; choice is centre- and patient-dependent.

3. Reverse total shoulder after proximal humeral resection. Improves active elevation compared with a hemiarthroplasty-type endoprosthesis, but requires an intact deltoid, functioning axillary nerve and preserved glenoid — conditions frequently not met after an oncological resection. Selection, not technique, determines the result.

4. Duration and intensity of surveillance. There is no evidence-based schedule. Late metastasis is well documented, but the yield of annual chest CT at 15 or 20 years and the cumulative radiation burden in a young patient are unquantified. Many units transition to lower-dose or lower-frequency imaging combined with a strong safety-netting message.

5. Role of particle (proton/carbon-ion) radiotherapy. Increasingly used for unresectable axial chondrosarcoma. Its role in clear cell chondrosarcoma specifically is essentially undefined given the rarity and the usually resectable appendicular location.

6. Molecular characterisation. Unlike conventional chondrosarcoma (IDH-mutant in a large proportion), clear cell chondrosarcoma lacks a defining driver. Whether it is a distinct entity biologically or a morphological pattern remains an open question, and there is currently no targeted therapy.